| 词条 | Shire (pharmaceutical company) | ||||||||||||||||||||||||||||||||||
| 释义 |
| name = Shire Plc | predecessor = Shire Pharmaceuticals Group Plc | logo = Shire logo.svg | image = | image_size = | image_caption = | type = Subsidiary | traded_as = {{NASDAQ was|SHPG}} | ISIN = JE00B2QKY057 | foundation = {{start date and age|1986}} | defunct = 2019 | industry = Pharmaceuticals | products = | revenue = $15,160.6 million (2017)[1] | operating_income = $2,455.2 million (2017)[1] | net_income = $4,271.5 million (2017)[1] | num_employees = 22,000 (2017)[2] | parent = Takeda Pharmaceutical Company | subsid = | homepage = www.shire.com | footnotes = }} Shire Plc was a Jersey-registered, Irish-headquartered global specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire had its primary listing on the London Stock Exchange. Shire has a secondary listing on NASDAQ. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019. Shire was a global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. The company's products were available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics. The original corporate headquarters was located in Basingstoke, Hampshire, England. Main offices are located in Dublin, Ireland, the United States in Cambridge, Massachusetts and Chicago, Illinois and in Zug, Switzerland. In addition, Shire owns manufacturing sites in Lexington, Massachusetts and Social Circle, Georgia. Shire’s headquarters in Lexington, MA will be integrated with Takeda’s new U.S. headquarters, which is being relocated from Deerfield, IL to the Boston area. HistoryEarly historyShire was founded in 1986 in the UK by four entrepreneurs: Harry Stratford, Dennis Stephens, Peter Moriarty, and Geoff Hall.[3] Under the management of Rolf Stahel Shire was first listed on the London Stock Exchange in 1996. Shire's initial products were calcium supplements (Calcichew-D3) for patients seeking to treat or prevent osteoporosis. In 1997 the company acquired Pharmavene for £105 million in order to access Pharmavene's drug delivery methods.[4] Later in the same year Shire acquired Richwood Pharmaceutical Company, forming Shire-Richwood Inc.[5] 2000 to 2009In 2001 the company acquired Biochem Canada.[6] Shire's next acquisition didn't come until 2005 when it acquired Transkaryotic Therapeutics[7] and two years later - in 2007 - New River Pharmaceuticals Inc, for a then company record of $2.6 billion.[8] With the purchase of New River, Shire gained access and ownership of Vyvanse. A year later the company acquired the German company Jerini, for $521 million. Jerini focused on treating hereditary angioedema.[9] In 2008, in reaction to new taxation measures announced by the Labour Party in the treatment of royalties on patents, the company moved its tax domicile to Dublin, Ireland.[10] 2010 onwards2010 saw a change in company strategy, with the company seeking to expand through mergers and acquisitions - culminating in the company becoming one of the most acquisitive in the industry. In 2010 the company acquired Movetis, a Belgian company focusing on gastrointestinal products for $565 million,[11] a year later it acquired regenerative medicine manufacturer Advanced BioHealing.[12] In 2012 the company acquired FerroKin BioSciences for $325 million along with FerroKins lead iron chelator - FBS0701.[13] 2013 saw the company complete its highest number of acquisitions with Lotus Tissue Repair, Inc. (lead compound, ABH001),[14] SARcode Bioscience Inc.,[15] with the last being ViroPharma. Shire changed the name of ViroPharma to Shire Viropharma Inc. upon acquisition and on their final day of trading the company was valued at $3.3 billion.[16] At $4.2 billion, ViroPharma set a new company record.[17] In 2014 Shire acquired two rare disease drug companies: Fibrotech[18] with its antifibrotic compounds for $75 million, and Lumena, a company researching rare gastro-intestinal and hepatic compounds, for $260 million.[19] In 2015, NPS Pharmaceuticals was acquired for $5.2 billion, bringing along its rare disease drugs Gattex and Natpara.[20] On their final day of trading, NPS had a market capitalisation of $4.99 billion. The company also acquired, later in the same year, Meritage Pharma for $245 million, Foresight Biotherapeutics for $300 million[21] and Dyax for $6.5 billion.[22][23] The purchases bolstered Shires gastro-intestinal and rare disease sectors, with Phase-III-ready treatment - Budesonide - for the treatment of eosinophilic esophagitis. As well as expanding the company's pipeline with a late-stage treatment candidate for infectious conjunctivitis with lead candidate FST-100 and increasing the company's rare disease catalogue with Dyax’s portfolio of plasma kallikrein inhibitors against hereditary angioedema (led by the approved drug Kalbitor and the Phase III DX-2930). In January 2016, the company made its most significant purchase, with the $32 billion acquisition of Baxalta (which had been spun-off from Baxter the previous year[24]), creating the largest global biotech company focused solely on rare diseases.[25] In April 2018, Shire agreed to sell its oncology business to French pharmaceutical company Servier for £1.7billion.[26] Aborted AbbVie takeoverOn 20 June 2014, Shire rejected a takeover attempt by AbbVie. AbbVie offered £46.11 per share (£27.3 billion or $46.5 billion in total).[27] On 8 July, the offer was increased to $51.5 billion.[28] On 18 July, it was announced that AbbVie would acquire Shire for $54.8 billion.[29] On 15 October, news broke suggesting AbbVie was reconsidering their proposed takeover deal due to changes in US "Tax Inversion" law [30] and on 16 October AbbVie's board recommended that shareholders vote against the deal.[31] This news sent Shire's share price down over 27%; however, AbbVie would be subject to a $1.6 billion break-up fee, payable to Shire.[32] On 21 October, the merger was called off.[33] Takeda takeoverIn April 2018, reported that Takeda Pharmaceutical Company had an approach to acquire Shire. Days later Shire announced they had rejected all three Takeda bids. The first bid valued the business at £41 billion (£28 per Shire shares paid in Takeda shares plus £16 per share in cash), the second £43 billion (£28.75 per Shire shares paid in Takeda shares plus £16.75 per share in cash) and the third £44 billion (£28 per Shire shares paid in Takeda shares plus £17.75 per share in cash).[34] Reuters also reported interest from Allergan[35] however they ruled themselves out a day later.[36] A day later Takeda increased their offer with a fourth bid, to £26 per Shire shares paid in Takeda shares plus £21 per share in cash - giving a total value of £44.3 billion ($62.1 billion).[37] On April 24, Takeda submitted an enhanced fifth bid for the company.[38] On April 25, Shire said that they will recommend the revised £45.8 billion ($64 billion) offer to their shareholders. The enhanced offer included a more generous cash component, with the deal offering £21.76 ($30.33) in cash for each Shire ordinary share.[39][40][41] The same day, GlaxoSmithKline ruled out making any form of counter-bid.[42] On 8 May 2018, an agreement was finally reached in which Shire was sold to Takeda in a $62 billion deal.[43][44] Takeda’s acquisition of Shire closed on 8 January 2019.[45] Acquisition history{{clade | style=font-size:90%;line-height:110% |thickness=0|label1=Shire Plc |1= {{clade |label1= |1=Baxalta (Acq 2016) |2= {{clade |label1= |1=Dyax (Acq 2015) |3= {{clade |label1= |1=Foresight Biotherapeutics (Acq 2015) |4= {{clade |label1= |1=Meritage Pharma (Acq 2015) |5= {{clade |label1= |1=Meritage Pharma (Acq 2015) |6= {{clade |label1= |1=NPS Pharmaceuticals (Acq 2015) |7= {{clade |label1= |1=Lumena (Acq 2014) |8= {{clade |label1= |1=Fibrotech (Acq 2014) |9= {{clade |label1=ViroPharma (Acq 2013) |1=Lev Pharmaceuticals (Acq 2008) |10= {{clade |label1= |1=SARcode Bioscience Inc (Acq 2013) |11= {{clade |label1= |1=Premacure AB (Acq 2013) |12= {{clade |label1= |1=Lotus Tissue Repair, Inc (Acq 2013) |13= {{clade |label1= |1=FerroKin BioSciences (Acq 2012) |14= {{clade |label1= |1=Advanced BioHealing (Acq 2011) |15= {{clade |label1= |1=Movetis (Acq 2012) |16= {{clade |label1= |1=Jerini (Acq 2008) |17= {{clade |label1= |1=New River Pharmaceuticals Inc (Acq 2007) |18= {{clade |label1= |1=Transkaryotic Therapeutics (Acq 2005) |19= {{clade |label1= |1=Biochem Canada (Acq 2001) |20= {{clade |label1= |1=Richwood Pharmaceutical Company (Acq 1997) |21= {{clade |label1= |1=Pharmavene (Acq 1997) }}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}} ProductsThe Annual Revenue figures in the following table were drawn from the company's 2015 preliminary results.[46]
Licences & RoyaltiesIn July 2014, Shire licensed the rights to the investigational Hunter syndrome compound, AGT-182, from ArmaGen for up to $225 million.[47] The Annual Revenue figures in the following Table were drawn from the company's 2015 preliminary results.[46]
Corporate leadershipFlemming Ørnskov, was the company's chief executive officer through January 8, 2019 with Takeda's Acquisition of Shire.[48] Ginger Gregory as Chief Human Resources Officer, Jeffrey Poulton as CFO, and Philip Vickers as Head of R&D.[49] James Bowling vacated his position as interim CFO in the aftermath of the collapse of the AbbVie inversion deal.[50] The Chair of Shire's Board of Directors was Susan Kilsby.[51]See also{{Portal|Companies}}
References1. ^1 2 {{cite web|url=https://www.shire.com/-/media/shire/shireglobal/shirecom/pdffiles/newsroom/2018/full-year-2017-results.pdf |title=Preliminary Results 2017|publisher=Shire|accessdate=17 March 2018}} 2. ^{{cite web|url=http://www.shire.com/shireplc/en/careers|title=Join Us|date=|work=shire.com|accessdate=12 April 2017}} 3. ^{{cite web|url=http://www.thesundaytimes.co.uk/sto/business/Industry/article830604.ece|title=Shire is one of the big stars|publisher=Sunday Times|date=27 November 2011|accessdate=26 March 2016}} 4. ^{{cite web|url=https://www.independent.co.uk/news/business/shire-buys-us-drugs-delivery-firm-for-pounds-105m-1280736.html|title=Shire buys US drugs delivery firm for pounds 105m|author=Grimond, Magnus |date=1997-02-26 | work=The Independent|accessdate=22 March 2016}} 5. ^{{cite web|url=https://www.independent.co.uk/news/business/investment-column-shire-focuses-on-buying-richwood-1243915.html|title=Investment Column: Shire focuses on buying Richwood|author=Grimond, Magnus|date=1997-08-04 | work=The Independent|accessdate=22 March 2016}} 6. ^{{cite web|url=https://www.telegraph.co.uk/finance/2717558/Canadians-give-go-ahead-for-Shire-takeover-of-BioChem.html|title=Canadians give go-ahead for Shire takeover of BioChem|author=Dunne, Helen |date=2001-05-10 | work=Telegraph.co.uk|accessdate=22 March 2016}} 7. ^{{cite web|url=http://www.readabstracts.com/Business-international/UK-drug-maker-agrees-to-buy-Transkaryotic-Hedge-Funds-vex-a-Shire-takeover-of-Transkaryotic.html|title=U.K. drug maker agrees to buy Transkaryotic|date=|work=readabstracts.com|accessdate=22 March 2016}} 8. ^{{cite web|url=http://www.pharmatimes.com/mobile/07-02-21/Shire_buys_New_River_Pharmaceuticals_for_2_6_billion.aspx|title=Shire buys New River Pharmaceuticals for $2.6 billion|date=|work=pharmatimes.com|accessdate=22 March 2016}} 9. ^{{cite web|url=http://www.fiercebiotech.com/story/shire-buy-jerini-521m-deal/2008-07-03|title=Shire to buy Jerini in $521M deal|date=|work=FierceBiotech|accessdate=22 March 2016}} 10. ^Shire moves to Ireland for tax Irish Examiner, April 2008 11. ^{{cite web|url=http://www.fiercebiotech.com/story/shire-forges-565m-buyout-deal-movetis/2010-08-03|title=Shire forges $565M buyout deal for Movetis|date=|work=FierceBiotech|accessdate=22 March 2016}} 12. ^{{cite web | author = Grogan, Kevin | date = 2011-05-18 | title = Shire swoops to buy Advanced BioHealing | url=http://www.pharmatimes.com/article/11-05-18/Shire_swoops_to_buy_Advanced_BioHealing.aspx | work=pharmatimes.com | accessdate=22 March 2016 | quote = }} 13. ^{{cite web|url=https://www.reuters.com/article/2012/03/15/us-shire-idUSBRE82E0K520120315|title=Shire to buy U.S. biotech firm for up to $325 million|author=Reuters Editorial|date=15 March 2012|work=Reuters|accessdate=22 March 2016}} 14. ^{{cite web|url=http://www.genengnews.com/gen-news-highlights/shire-acquires-lotus-tissue-repair/81247840/|title=Shire Acquires Lotus Tissue Repair|date=8 January 2013|publisher=GEN|accessdate=26 March 2016}} 15. ^{{cite web|url=https://www.bloomberg.com/news/articles/2013-03-25/shire-to-buy-eye-drug-maker-sarcode-for-160-million|title=Shire to Buy Eye-Drug Maker SARcode for $160 Million|date=25 March 2013|publisher=Bloomberg|accessdate=26 March 2016}} 16. ^{{cite web|url=https://www.bloomberg.com/news/articles/2013-11-11/shire-agrees-to-buy-viropharma-for-about-4-2-billion-1-|title=Shire Buys ViroPharma for $4.2 Billion to Add Orphan Drug|date=11 November 2013|publisher=Bloomberg|accessdate=26 March 2016}} 17. ^{{cite web|url=https://www.bloomberg.com/news/2013-11-11/shire-agrees-to-buy-viropharma-for-about-4-2-billion-1-.html|title=Shire Buys ViroPharma for $4.2 Billion to Add Orphan Drug|author1=Trista Kelley |author2=Makiko Kitamura |lastauthoramp=yes |date=11 November 2013|work=Bloomberg.com|accessdate=22 March 2016}} 18. ^{{cite web|url=http://www.fiercebiotech.com/press-releases/fibrotech-acquired-shire-us75m-plus-milestones|title=Fibrotech acquired by Shire for US$75M plus milestones|work=FierceBiotech}} 19. ^{{cite web|url=http://www.genengnews.com/gen-news-highlights/shire-acquires-lumena-for-260m/81249851/|title=GEN - News Highlights:Shire Acquires Lumena for $260M+|work=GEN}} 20. ^{{cite web|url=https://www.bbc.co.uk/news/business-30772280|title=UK drug firm Shire to buy US rival in $5.2bn deal|date=|work=BBC News|accessdate=22 March 2016}} 21. ^{{cite web|url=http://www.genengnews.com/gen-news-highlights/shire-acquires-foresight-biotherapeutics-for-300m/81251584/|title=Shire Acquires Foresight Biotherapeutics for $300M|date=|work=GEN|accessdate=22 March 2016}} 22. ^{{cite web|url=http://www.businesswire.com/news/home/20151202006452/en/|title=Dyax Corp. Announces Early Termination of Hart-Scott-Rodino Waiting Period - Business Wire|date=2 December 2015|work=businesswire.com|accessdate=22 March 2016}} 23. ^{{cite web|url=http://www.genengnews.com/gen-news-highlights/shire-to-acquire-dyax-for-up-to-6-5b/81251922|title=Shire to Acquire Dyax for Up to $6.5B|date=|work=GEN|accessdate=22 March 2016}} 24. ^{{cite web|title=Baxter’s Board of Directors Approves Separation of Baxalta and Declares Special Dividend of Baxalta Stock|url=http://investor.baxter.com/phoenix.zhtml?c=86121&p=irol-newsArticle&id=2056943|website=investor.baxter.com|publisher=Baxter International Inc.}} 25. ^{{cite web|url=http://www.genengnews.com/gen-news-highlights/shire-baxalta-tie-the-knot-in-32b-merger/81252213/|title=Shire, Baxalta Tie the Knot in $32B Merger|date=|work=GEN|accessdate=22 March 2016}} 26. ^{{cite news|last1=Javed|first1=Ayesha|title=Shire sells oncology unit for £1.7bn as Takeda boss prepares potential bid|url=https://www.telegraph.co.uk/business/2018/04/16/shire-sells-oncology-unit-17bn-takeda-boss-prepares-potential/|accessdate=16 April 2018|publisher=The Telegraph|date=16 April 2018}} 27. ^{{cite web|url=https://www.bloomberg.com/news/2014-06-20/abbvie-offered-46-5-billion-for-shire-as-bid-rejected.html|title=AbbVie Said to Consider New Bid After Shire Rejects Offer|author1=David Welch, Matthew Campbell |author2=Simeon Bennett |lastauthoramp=yes |date=21 June 2014|work=Bloomberg}} 28. ^{{cite web|url=https://www.bloomberg.com/news/2014-07-08/abbvie-raises-offer-for-shire-to-51-5-billion.html|title=AbbVie Raises Offer for Shire to $51.5 Billion|author1=Caroline Chen, Drew Armstrong |author2=Simeon Bennett |lastauthoramp=yes |date=8 July 2014|work=Bloomberg}} 29. ^{{cite web|url=https://www.bloomberg.com/news/2014-07-18/abbvie-to-buy-shire-for-54-8-billion-as-drug-deals-surge.html|title=AbbVie Is Biggest to Quit U.S. Address in $55 Billion Shire Deal|author1=Simeon Bennett |author2=Caroline Chen |lastauthoramp=yes |date=19 July 2014|work=Bloomberg}} 30. ^{{cite web|url=https://www.bloomberg.com/news/2014-10-15/abbvie-reconsidering-shire-sends-inversion-targets-down.html|title=AbbVie Reconsidering Shire Sends Inversion Targets Down|author1=Albertina Torsoli, Kristen Hallam |author2=Oliver Staley |lastauthoramp=yes |date=15 October 2014|work=Bloomberg}} 31. ^{{cite web|url=https://www.bloomberg.com/news/2014-10-15/abbvie-said-close-to-shire-reversal-as-tax-rules-change.html|title=AbbVie Board Recommends Holders Vote Against Shire Deal|author1=Albertina Torsoli, Manuel Baigorri |author2=Matthew Campbell |lastauthoramp=yes |date=16 October 2014|work=Bloomberg}} 32. ^{{cite web|url=https://www.bloomberg.com/news/2014-10-16/abbvie-board-recommends-holders-vote-against-shire-deal.html|title=Shire Shares Extend Drop After AbbVie Backtracks on Deal|author1=Albertina Torsoli, Manuel Baigorri |author2=Matthew Campbell |lastauthoramp=yes |date=16 October 2014|work=Bloomberg}} 33. ^{{cite news | url=http://www.genengnews.com/gen-news-highlights/abbvie-shire-call-off-51-7b-merger/81250493/ | title=AbbVie, Shire Call Off $51.7B Merger | work=Gen. Eng. Biotechnol. News | department=GEN News Highlights | date=21 October 2014 | author=Philippidis, Alex }} 34. ^{{cite web|url=https://www.shire.com/en/newsroom/2018/april/mdt9go|title=Statement re Proposal from Takeda Pharmaceutical Company Limited|website=www.shire.com}} 35. ^{{cite web|url=https://uk.reuters.com/article/us-shire-m-a-takeda-pharma-bid/allergan-moves-in-as-shire-rebuffs-63-billion-takeda-bid-sources-idUKKBN1HQ1PN|title=Shire rejects $63 billion Takeda bid as Allergan drops pursuit|first=Greg|last=Roumeliotis|publisher=}} 36. ^{{cite web|url=https://uk.reuters.com/article/uk-shire-m-a-allergan-exclusive/exclusive-allergan-in-talks-to-acquire-shire-competing-against-takeda-sources-idUKKBN1HQ218|title=Exclusive - Allergan in talks to acquire Shire, competing against...|first=Reuters|last=Editorial|publisher=}} 37. ^{{cite web|url=https://uk.reuters.com/article/us-shire-m-a-takeda/japans-takeda-nudges-up-shire-offer-to-47-pounds-a-share-idUKKBN1HR00T|title=Japan's Takeda sweetens $62 billion Shire offer|first=Sam|last=Nussey|publisher=}} 38. ^{{cite web|url=https://uk.reuters.com/article/uk-shire-m-a-takeda-pharma/shire-receives-new-bid-from-takeda-as-takeover-deadline-looms-idUKKBN1HV1FY|title=Shire willing to back $64 billion Takeda bid, market signals doubts|first=Ben|last=Martin|publisher=}} 39. ^{{cite web|url=https://www.bbc.co.uk/news/business-43889437|title=Shire backs Takeda's £46bn offer|date=25 April 2018|publisher=|via=www.bbc.co.uk}} 40. ^{{cite web|url=https://uk.reuters.com/article/uk-shire-m-a-takeda-pharma-deal-exclusiv/shire-willing-to-back-64-billion-takeda-bid-market-signals-doubts-idUKKBN1HV2OQ|title=Shire willing to back $64 billion Takeda bid, market signals doubts|first=Ben|last=Martin|publisher=}} 41. ^{{cite web|url=https://uk.reuters.com/article/us-takeda-strategy-analysis/shire-bid-marks-takedas-latest-and-biggest-push-for-global-status-idUKKBN1HW11A|title=Shire bid marks Takeda's latest - and biggest - push for global status|first=Sam|last=Nussey|publisher=}} 42. ^{{cite web|url=https://uk.reuters.com/article/us-shire-m-a-takeda-pharma-gsk/gsk-rules-out-entering-shire-takeover-battle-idUKKBN1HW1JT|title=GSK rules out entering Shire takeover battle|first=Reuters|last=Editorial|publisher=}} 43. ^{{Cite news|url=https://www.bloomberg.com/news/articles/2018-05-08/takeda-inks-62-billion-deal-to-buy-shire-for-cash-and-shares|title=Takeda Clinches $62 Billion Deal to Buy Drugmaker Shire|work=Bloomberg.com|access-date=2018-05-08|language=en}} 44. ^{{Cite news|url=https://www.reuters.com/article/us-shire-m-a-takeda/japans-takeda-agrees-62-billion-takeover-of-shire-idUSKBN1I90IC|title=Japan's Takeda agrees $62 billion takeover of Shire|last=Editorial|first=Reuters|work=U.S.|access-date=2018-05-08|language=en-US}} 45. ^{{cite web|url=http://www.pharmatimes.com/news/takeda_completes_shire_acquisition_1274243|title=Takeda completes Shire acquisition|date=8 January 2019|publisher=Pharma Times|accessdate=24 January 2019}} 46. ^1 {{cite web|url=http://investors.shire.com/~/media/Files/S/Shire-IR/quarterly-reports/2016/full-year-2015-results-press-release.pdf |title=Preliminary Results 2015|publisher=Shire|accessdate=26 March 2016}} 47. ^{{cite web|url=http://www.genengnews.com/gen-news-highlights/armagen-licenses-agt-182-rights-to-shire-for-up-to-225m/81250142/?kwrd=Shire|title=GEN - News Highlights:ArmaGen Licenses AGT-182 Rights to Shire for Up to $225M|work=GEN}} 48. ^{{cite news | author=Bennett, Simeon | title=Shire’s New CEO Adds Sales Staff, Damps Takeover Talk | date=2013-06-10 | agency=Bloomberg Business News | url=https://www.bloomberg.com/news/articles/2013-06-10/shire-s-new-ceo-adds-sales-staff-damps-takeover-talk | access-date=22 March 2016 }} 49. ^{{cite web | author = Shire Staff | date = 2016-03-22 | url=https://www.shire.com/who-we-are/leadership/executive-committee | title=Leadership: Executive Committee | publisher=Shire | accessdate=13 February 2015 }} 50. ^{{cite news |author1=Schaps, Karolin |author2=Hirschler, Ben |lastauthoramp=yes | date = 2014-10-20 | title=Shire CFO to leave drugmaker as AbbVie drops bid | agency=Reuters | url=https://www.reuters.com/article/us-shire-moves-cfo-idUSKCN0I90M720141020 | access-date = 22 March 2016 }} 51. ^{{cite web | author = Shire Staff | date = 2016-03-22 | url=https://www.shire.com/who-we-are/leadership/board-of-directors | title=Leadership: Board of Directors | publisher=Shire | access-date=22 March 2016 }} External links
| name = Shire plc | sec_cik = 0000936402 }}{{authority control}}{{Pharmaceutical industry in the United Kingdom}}{{Philadelphia Corporations}}{{Use DMY dates|date=February 2016}}{{Use British English|date=February 2016}}{{DEFAULTSORT:Shire Plc}} 18 : Pharmaceutical companies established in 1986|Pharmaceutical companies of Ireland|Pharmaceutical companies of the United Kingdom|Biotechnology companies of Ireland|Biotechnology companies of the United Kingdom|Biotechnology companies established in 1986|Companies of Jersey|Companies based in Dublin (city)|Companies based in Basingstoke|Companies formerly listed on the London Stock Exchange|Companies formerly listed on NASDAQ|Multinational companies|1986 establishments in Ireland|1986 establishments in Jersey|Orphan drug companies|Life sciences industry|British companies established in 1986|2019 mergers and acquisitions |
||||||||||||||||||||||||||||||||||
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。